Answers are grounded in this paper and cite their sources.
Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).
No takes yet. Share an insight, caveat, or question.
Filocamo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: